Sarah Jackson


AI supporting clinicians in the diagnosis of cardiovascular disease Diagnostic capability Our goal is to increase the diagnostic accuracy of cardiovascular disease and improve the lives of people globally SEE OUR TECHNOLOGY Clinical trials Clinical trials in the US and UK are in the process of validating the accuracy of EchoGo** SEE OUR PROGRESS Workflow …

Home Read More »

Ultromics receives FDA clearance

  Ultromics receives FDA clearance for its AI-powered decision support system, EchoGo Core.   AI automates cardiac analysis helping earlier detection of cardiovascular disease, enabling clinicians to improve patient care and outcomes.   Ultromics, the UK-based health technology firm at the forefront of applying artificial intelligence to echocardiography, has received 510(K) clearance from the U.S. …

Ultromics receives FDA clearance Read More »


The EchoGo* Platform An automated platform which enables clinicians to interpret echocardiograms efficiently and accuratelyImproves patient outcomes Assists clinicians in making decisions that can improve care delivery and outcomesDrives quality Automates complex measurements, standardizing the quality of image interpretationReduces variability Allows clinicians with a wide range of experience to consistently interpret cardiac parameteres and improve …

Platform Read More »

Artificial intelligence will improve medical treatments

FOUR years ago a woman in her early 30s was hit by a car in London. She needed emergency surgery to reduce the pressure on her brain. Her surgeon, Chris Mansi, remembers the operation going well. But she died, and Mr Mansi wanted to know why. He discovered that the problem had been a four-hour delay in getting her from the accident and emergency unit of the hospital where she was first brought, to the operating theatre in his own hospital…

Ultromics secures £10 million investment to bring AI heart diagnostics to hospitals

Ultromics, the UK start-up behind breakthrough artificial intelligence (AI) technology for the diagnosis of coronary heart disease, has raised £10 million in Series-A investment. The funding was led by Oxford Sciences Innovation (OSI), with Neptune, RT Ventures, GT Healthcare, Tanarra, Fushia and personal investors Andre Crawford-Brunt and Dieter Spälti also participating.